Android app Apple app link

Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs

By CNBC   |   1 month ago
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs

Bristol Myers Squibb reported exceptional third-quarter earnings exceeding expectations, driven by Eliquis and growth portfolio drugs. The company raised revenue and earnings guidance for 2024 amidst cost-cutting efforts to enhance key drug brands and R&D programs.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.